| Author | Lemos, Livia Lovato Pires | |
| Author | Costa, Juliana de Oliveira | |
| Author | Almeida, Alessandra Maciel | |
| Author | Oliveira Junior, Haliton | |
| Author | Barbosa, Mariana Michel | |
| Author | Kakehasi, Adriana Maria | |
| Author | Acurcio, Francisco de Assis | |
| Access date | 2015-06-25T16:09:27Z | |
| Available date | 2015-06-25T16:09:27Z | |
| Document date | 2014 | |
| Citation | LEMOS, Livia Lovato Pires et al. Treatment of psoriatic arthritis with anti‑TNF agents:a systematic review and meta‑analysis of efficacy,effectiveness and safety. Rheumatol Int, vol. 34, n. 10, p. 1345-1360. 2014 | pt_BR |
| ISSN | 0172-8172 | |
| URI | https://www.arca.fiocruz.br/handle/icict/10965 | |
| Language | eng | pt_BR |
| Publisher | Springer International | pt_BR |
| Rights | restricted access | pt_BR |
| Title | Treatment of psoriatic arthritis with anti‑TNF agents: a systematic review and meta‑analysis of efficacy, effectiveness and safety | pt_BR |
| Type | Article | |
| DOI | 10.1007/s00296-014-3006-2 | |
| Abstract | We did a systematic review and meta-analysis on the efficacy and safety of the anti-TNF drugs adalimumab, etanercept, golimumab and infliximab used in psoriatic arthritis (PsA) adult treatment. Additionally, we present results of anti-TNF use in real life settings.
We searched Embase, Medline, Cochrane Central and LILACS, from inception to 11/08/2013, for studies comparing anti-TNFs with each other or with controls. We included nine randomized controlled trials and six observational studies. ACR20, ACR50, PsARC and PASI75 responses were achieved by more users of anti-TNF than control after up to 24 weeks of treatment. More participants who used etanercept and infliximab achieved ACR70. After all patients originally randomized to anti-TNF or placebo had used anti-TNF for at least 24 weeks, we observed difference only with regard to ACR70 response. Radiographic end points were achieved by more patients in anti-TNF group, and they seem to be time dependent—the longer patients use the drug the better the results. Etanercept and infliximab had worse results on application site reactions, but in general anti-TNF drugs in the regimens studied were as safe as control/placebo. There seems to be no difference in efficacy and effectiveness among anti-TNFs, but superiority head-to-head studies are still needed. Meanwhile, other factors should be taken into account in the choice of medication, such as costs and patient convenience. | pt_BR |
| Affilliation | Universidade Federal de Minas Gerais. Faculdade de Farmácia. Programa de Pos‑graduacao em Medicamentos e Assistência Farmacêutica. Belo Horizonte, MG, Brazil/Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Centro Colaborador do SUS – CCATES. Belo Horizonte, MG, Brazil | pt_BR |
| Affilliation | Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Centro Colaborador do SUS – CCATES. Belo Horizonte, MG, Brazil | pt_BR |
| Affilliation | Universidade Federal de Minas Gerais. Faculdade de Medicina. Departamento de Medicina Preventiva e Social. Belo Horizonte, MG, Brazil | pt_BR |
| Affilliation | Universidade Federal de Minas Gerais. Faculdade de Farmácia. Programa de Pos‑graduacao em Medicamentos e Assistência Farmacêutica. Belo Horizonte, MG, Brazil | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisa René Rachou. Programa de Pos‑Graduacao em Saúde Coletiva. Belo Horizonte, MG, Brazil/ Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brazil | pt_BR |
| Affilliation | Universidade Federal de Minas Gerais. Faculdade de Medicina. Departamento do Aparelho Locomotor. Belo Horizonte, MG, Brazil | pt_BR |
| Affilliation | Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Belo Horizonte, MG, Brazil. | pt_BR |
| Subject | Psoriatic arthritis | pt_BR |
| Subject | Spondyloarthropathy | pt_BR |
| Subject | Systematic review | pt_BR |
| Subject | Meta-analysis | pt_BR |
| Subject | Anti-TNF | pt_BR |
